NET

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

Retrieved on: 
Wednesday, March 13, 2024
Dopamine, NET, Reward, Sheba Medical Center, CWY, Psychiatry, Serotonin, Patient, Research, MEAI, Alcoholism, Clinical trial, DAT, Safety, Norepinephrine, Yale school, Therapy, Ministry, Pharmaceutical industry

The approval, previously announced on February 23, 2024, allows Clearmind to start its pioneering clinical trial.

Key Points: 
  • The approval, previously announced on February 23, 2024, allows Clearmind to start its pioneering clinical trial.
  • The clinical trial is a multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic study of CMND-100 in healthy volunteers and AUD subjects.
  • The Clearmind team has been working tirelessly on the research and development of a novel treatment to the global epidemic of alcoholism.
  • We are eager to continue our work with patients in need of help,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

NET Power Reports Fourth Quarter and Year End 2023 Results and Provides Business Update

Retrieved on: 
Monday, March 11, 2024
Environment, Other Energy, Environmental Health, Utilities, Oil, Gas, Alternative Energy, Sustainability, Green Technology, Energy, Permian, FEED, NET, Partnership, ASU, EPC, Occidental Petroleum, Investment, Engineering, Rare-earth element

NET Power Inc. (NYSE: NPWR) (“NET Power” or the “Company”) today reported results for the fourth quarter and year end 2023.

Key Points: 
  • NET Power Inc. (NYSE: NPWR) (“NET Power” or the “Company”) today reported results for the fourth quarter and year end 2023.
  • Danny Rice, Chief Executive Officer of NET Power, commented, “Our team concluded the fourth quarter of 2023 with steady progress across our three strategic pillars.
  • “2023 was a historic year for NET Power, which included completing our business combination with Rice Acquisition Corp. II and becoming a publicly listed company on the NYSE in June.
  • NET Power will host a conference call to discuss fourth quarter and year end 2023 financial results beginning at 8:30 AM ET on Tuesday, March 12.

MESCIUS inc. Launches ActiveReports .NET v18

Retrieved on: 
Thursday, March 28, 2024
NET, ActiveReports, UI

PITTSBURGH, March 28, 2024 /PRNewswire/ -- MESCIUS inc., a global provider of award-winning enterprise software development tools, is pleased to announce the release of ActiveReports.

Key Points: 
  • PITTSBURGH, March 28, 2024 /PRNewswire/ -- MESCIUS inc., a global provider of award-winning enterprise software development tools, is pleased to announce the release of ActiveReports.
  • ActiveReports.
  • Read the release announcement from ActiveReports .NET to learn more about the new theme support in v18.
  • With v18, ActiveReports.

VNET Reports Unaudited Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Research, NET, PIN, Employment, The Company, CASH, Growth, H.10, RMB, LOSS, Acquisition, IDC, AI, ADS, Translation, Bank statement, Investment, Note, GAAP, Depreciation, VNET, Debt-to-GDP ratio, USD, Marketing, Video game

BEIJING, March 27, 2024 /PRNewswire/ -- VNET Group, Inc. (Nasdaq: VNET) ("VNET" or the "Company"), a leading carrier- and cloud-neutral internet data center services provider in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • BEIJING, March 27, 2024 /PRNewswire/ -- VNET Group, Inc. (Nasdaq: VNET) ("VNET" or the "Company"), a leading carrier- and cloud-neutral internet data center services provider in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2023.
  • Qiyu Wang, Chief Financial Officer of VNET, commented, "We delivered robust 2023 results through our strategic focus on high-quality revenues.
  • Retail IDC MRR[2] per cabinet was RMB9,477 in the fourth quarter of 2023, compared with RMB9,495 in the third quarter of 2023 and RMB9,371 in the fourth quarter of 2022.
  • GROSS PROFIT: Gross profit in the fourth quarter of 2023 was RMB290.9 million (US$41.0 million), compared with RMB328.4 million in the same period of 2022.

Central Pattana, Thailand's No. 1 developer, aims to increase retail space in Bangkok by 2.2 million square meters, unveiling a 121 billion-Baht investment over the next five years

Retrieved on: 
Monday, March 25, 2024
NET, CRM, Ecosystem, Phra Pathommachedi, Growth, Intelligence, Partnership, The Cheesecake Factory, CentralPlaza Bangna, Shake Shack, Gateway, CentralWorld, Central Chaengwattana, PopMart Tour, Commercial, Quality of life, CPN, Marketing, CentralPlaza Pinklao, City, Behavior, Investment, Dusit Central Park, Residence, Central Pattana, Tourism, Central Rattanathibet, Heart, All, Dusit Thani Bangkok, BIZ

Last year, we achieved success in terms of annual performance with revenue of 46,790 million baht, a 26% increase from the previous year.

Key Points: 
  • Last year, we achieved success in terms of annual performance with revenue of 46,790 million baht, a 26% increase from the previous year.
  • Over the next 5 years, from 2024 to 2028, a total investment of 121,000 million baht is scheduled.
  • This year, we are undertaking a turnaround of shopping centers strategically located around the Bangkok Metropolitan Area: Central Pinklao, Central Bangna, Central Chaengwattana, Central Rattanathibet.
  • Central Pattana Public Company Limited (CPN), is striving towards the future under the brand purpose of "Imagining better futures for All."

Central Pattana, Thailand's No. 1 developer, aims to increase retail space in Bangkok by 2.2 million square meters, unveiling a 121 billion-Baht investment over the next five years

Retrieved on: 
Monday, March 25, 2024
NET, CRM, Ecosystem, Phra Pathommachedi, Growth, Intelligence, Partnership, The Cheesecake Factory, CentralPlaza Bangna, Shake Shack, Gateway, CentralWorld, Central Chaengwattana, PopMart Tour, Commercial, Quality of life, CPN, Marketing, CentralPlaza Pinklao, City, Behavior, Investment, Dusit Central Park, Residence, Central Pattana, Tourism, Central Rattanathibet, Heart, Multimedia, All, Dusit Thani Bangkok, BIZ

Last year, we achieved success in terms of annual performance with revenue of 46,790 million baht, a 26% increase from the previous year.

Key Points: 
  • Last year, we achieved success in terms of annual performance with revenue of 46,790 million baht, a 26% increase from the previous year.
  • Over the next 5 years, from 2024 to 2028, a total investment of 121,000 million baht is scheduled.
  • This year, we are undertaking a turnaround of shopping centers strategically located around the Bangkok Metropolitan Area: Central Pinklao, Central Bangna, Central Chaengwattana, Central Rattanathibet.
  • Central Pattana Public Company Limited (CPN), is striving towards the future under the brand purpose of "Imagining better futures for All."

America’s Car-Mart Reports Third Quarter Fiscal 2024 Results

Retrieved on: 
Friday, March 8, 2024
Acquisition, Collection, NET, LOS, Weather, Investment, SALES, Transport, Jules Kroll, Cox Enterprises, Partnership, Video game

ROGERS, Ark., March 08, 2024 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) (“we,” “Car-Mart” or the “Company”), today reported financial results for the third quarter ended January 31, 2024.

Key Points: 
  • ROGERS, Ark., March 08, 2024 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) (“we,” “Car-Mart” or the “Company”), today reported financial results for the third quarter ended January 31, 2024.
  • Note: Discussions in each section provide third quarter comparisons from fiscal year 2023 to fiscal year 2024.
  • SALES – Sales for the quarter were 11,664 units vs. 14,508 units, down 19.6% compared to the prior year quarter.
  • Sequentially, net charge-offs improved 40 basis points from 7.2% for the second quarter of fiscal 2024.

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023

Retrieved on: 
Monday, February 26, 2024
Borderline personality disorder, HOPE, HDAC6, National Cancer Institute, EVOLUTION, CMT, Agitation, Data analysis, Convertible bond, ICIS, ALS, SCLC, Azacitidine, Duration, ICI, IIS, Sciatic nerve, Deficit spending, Paclitaxel, DSM-IV codes, Development, Genomics, ALS Association, FMS, LSD1, AML, Clinical Global Impression, MSKCC, Conference, Aggression, Safety, Biomarker, CNS, Venetoclax, CRADA, OHSU, MRD, Clinical trial, BPD, Measure (mathematics), IND, FCCC, Dor, Human, Innovation, EMA, Kabuki syndrome, NET, NCI, Aes, Glomus tumor, FDA, GST, Food, Platinum, Schizophrenia, Phase II, Charcot–Marie–Tooth disease, Medicine, Patient, BEST, Disease, Pharmaceutical industry

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.
  • Research and development (R&D) expenses were $3.9 and $16.6 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $5.0 and $18.1 million for the quarter and twelve months ended December 31, 2022.
  • General and administrative expenses were $1.2 and $4.2 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.2 and $4.8 million for the quarter and twelve months ended December 31, 2022.
  • Net losses were $1.4 and $5.0 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.6 and $5.9 million for the quarter and twelve months ended December 31, 2022.

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Retrieved on: 
Friday, February 23, 2024
Therapy, Reward, Alcoholism, Ministry, NET, Serotonin, Dopamine, Norepinephrine, Safety, MEAI, CWY, Patient, Clinical trial, Yale school, DAT, Psychiatry, Sheba Medical Center, Research, Pharmaceutical industry

Vancouver, Canada, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce it has received approval from the Ministry of Health of Israel to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's proprietary MEAI-based (5-methoxy-2-aminoindane) CMND-100 oral capsule.

Key Points: 
  • "We are thrilled to receive approval to commence our phase I/IIa clinical trial for our lead drug candidate, CMND-100, which has been shown to be safe and effective in preclinical studies.
  • This is the most important milestone for the company to date and marks our transition to a clinical- stage pharmaceutical company.
  • The Clearmind team has been working tirelessly on the research and development of a novel treatment to the global epidemic of alcoholism.
  • We are eager to continue our work with patients in need of help,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

NET Power Schedules Fourth Quarter and Year End 2023 Earnings Release and Conference Call

Retrieved on: 
Tuesday, February 20, 2024
Alternative Energy, Energy, Utilities, Oil, Gas, NET

NET Power Inc. (NYSE: NPWR) plans to report its fourth quarter and year end 2023 financial results after market close on Monday, March 11, 2024, and will host a conference call to discuss the results beginning at 8:30 AM ET on Tuesday, March 12, 2024.

Key Points: 
  • NET Power Inc. (NYSE: NPWR) plans to report its fourth quarter and year end 2023 financial results after market close on Monday, March 11, 2024, and will host a conference call to discuss the results beginning at 8:30 AM ET on Tuesday, March 12, 2024.
  • To access the live audio webcast of the conference call, please visit NET Power’s investor relations website at ir.netpower.com.
  • To participate by phone, dial 877-407-8014 (domestic) or +1 201-689-8053 (international).
  • An archived webcast will be available following the call.